Viyash Scientific Limited has announced the appointment of Mr. Amit Jain and Mr. Abhiroop Jayanthi as Additional Directors, both representing the Carlyle group, effective April 22, 2026. In addition to these leadership changes, the company’s Board has approved a revision to the Employee Stock Option Scheme (ESOP) 2026, adjusting the total option pool to 1,30,98,000 stock options. These strategic moves aim to bolster governance and align long-term employee incentives with company growth.
Strengthening Board Leadership
On April 22, 2026, the Board of Directors of Viyash Scientific Limited officially appointed two new members to its leadership team. Mr. Amit Jain and Mr. Abhiroop Jayanthi join the company as Non-Executive, Non-Independent Directors. Both appointees bring significant expertise in private equity and investment management from their roles within the Carlyle group.
Strategic Background of Appointees
Mr. Amit Jain, a Partner and Head of Carlyle India Advisors, has an extensive background in the technology, consumer, and industrial sectors. He previously served at Blackstone and McKinsey & Company. His appointment is expected to provide valuable insights into buyout and control investments.
Mr. Abhiroop Jayanthi, a Managing Director at Carlyle, specializes in the healthcare, life sciences, and advanced manufacturing sectors. With 15 years of private equity experience and a history of leadership at Bain Capital, his inclusion is set to support the company’s strategic initiatives in its core focus areas.
Revised Employee Stock Option Scheme
During the same meeting, the Board addressed updates to the Employee Stock Option Scheme 2026 (ESOP 2026). To better align with company objectives, the Board approved a reduction in the option pool from the previously proposed 1,34,75,000 to 1,30,98,000 stock options. This revision reflects the company’s refined approach to long-term talent retention and equity-based compensation.
Source: BSE
